Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity
Open Access
- 22 August 2017
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 153 (1) , 118-132
Abstract
Summary: Unwanted immune responses against protein therapeutics can reduce efficacy or lead to adverse reactions. T‐cell responses are key in the development of such responses, and are directed against immunodominant regions within the protein sequence, often associated with binding to several allelic variants of HLA class II molecules (promiscuous binders). Herein, we report a novel computational strategy to predict ‘de‐immunized’ peptides, based on previous studies of erythropoietin protein immunogenicity. This algorithm (or method) first predicts promiscuous binding regions within the target protein sequence and then identifies residue substitutions predicted to reduce HLA binding. Further, this method anticipates the effect of any given substitution on flanking peptides, thereby circumventing the creation of nascent HLA‐binding regions. As a proof‐of‐principle, the algorithm was applied to Vatreptacog α, an engineered Factor VII molecule associated with unintended immunogenicity. The algorithm correctly predicted the two immunogenic peptides containing the engineered residues. As a further validation, we selected and evaluated the immunogenicity of seven substitutions predicted to simultaneously reduce HLA binding for both peptides, five control substitutions with no predicted reduction in HLA‐binding capacity, and additional flanking region controls. In vitro immunogenicity was detected in 21·4% of the cultures of peptides predicted to have reduced HLA binding and 11·4% of the flanking regions, compared with 46% for the cultures of the peptides predicted to be immunogenic. This method has been implemented as an interactive application, freely available online at http://tools.iedb.org/deimmunization/.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (HHSN272201200010C)
This publication has 71 references indexed in Scilit:
- Removing T-cell epitopes with computational protein designProceedings of the National Academy of Sciences, 2014
- Evaluating the Immunogenicity of Protein Drugs by ApplyingIn VitroMHC Binding Data and the Immune Epitope Database and Analysis ResourceJournal of Immunology Research, 2013
- Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesProceedings of the National Academy of Sciences, 2011
- Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass AllergenThe Journal of Immunology, 2010
- Deimmunization of Monoclonal Antibodies2008
- Rationally Engineered Therapeutic Proteins with Reduced ImmunogenicityThe Journal of Immunology, 2005
- Characterization of HLA DR13-restricted CD4+ T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis BJournal of General Virology, 2002
- Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.Journal of Experimental Medicine, 1994
- The inhibition of different T cell lines specific for the same antigen with TCR antagonist peptides.The Journal of Immunology, 1993
- Functional consequences of engagement of the T cell receptor by low affinity ligandsThe Journal of Immunology, 1993